eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2001
vol. 5
 
Share:
Share:
abstract:

Anagrelide, a novel agent in the treatment of essential thrombocythemia

Jolanta Wieczorek
,
Urszula Nowicka

Współcz Onkol (2001) vol. 5, 4 (152-155)
Online publish date: 2003/07/16
View full text Get citation
 
Essential thrombocythemia (ET), like polycythemia vera, chronic myelogenous leukemia, myelofibrosis, belongs to the chronic myeloproliferative disorders (MPD). ET is less likely than other MPDs to convert spontaneusly to acute leukemia. Like the other MPDs, however, bleeding and thrombosis are major causes of morbidity and mortality. Platelet-lowering agents currently used in ET include hydroxyurea, pipobroman, INFα, busulfan, radiophosphorus. Anagrelide is a neworal imidazoquinazoline derivative approved for use in ET and other MPDs as a platelet-lowering agent. The mechanism of action may involve the drug's interference with megacaryocyte maturation. More than 90% of patients with ET respond to anagrelide therapy regardless of the presence r absence of previous therapy. The responses are durable with median maintenence dose of aproximately 2 to 2.5 mg/day. Side efects are related mostly to the drug's vasodilating and positive inotropic efects. The place of anagrelide therapy in the current management of patients with ET is discussed.
keywords:

mieloproliferative diseases, essential thrombocythemia, anagrelide

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.